ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Camrelizumab Plus Apatinib in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma: An Open-Label, Single-Arm, Phase II Study

Ding, Xi; Zhang, Wei-Jing; You, Rui; Zou, Xiong; Wang, Zhi-Qiang; Ouyang, Yan-Feng; Peng, Lan; Liu, You-Ping; Duan, Chong-Yang; Yang, Qi; Lin, Chao; Xie, Yu-Long; Chen, Si-Yuan; Liu, Yong-Long; Gu, Chen-Mei; Xie, Ruo-Qi; Huang, Pei-Yu; Hong, Ming-Huang; Hua, Yi-Jun; Chen, Ming-Yuan南方医科大学; 中山大学; 1
Journal of Clinical Oncology2023-5-10DOI: 10.1200/JCO.22.01450
15被引5阅读
引用收藏
分享

摘要

PURPOSEImmune checkpoint inhibitors combined with antiangiogenic therapy reportedly have potential synergistic antitumor activity. We investigated the activity and safety of this regimen for recurrent/metastatic nasopharyngeal carcinoma (NPC).METHODSThis single-arm, Simon two-stage study enrolled patients with recurrent/metastatic NPC who were refractory to at least first-line systemic therapy and treatment-naive to immune checkpoint inhibitors. The patients received camrelizumab 200 mg once every 3 weeks and apatinib 250 mg once per day. The primary end point was the objective response rate. Key secondary end points included disease control rate, progression-free survival, duration of response, overall survival, and safety.RESULTSBetween October 14, 2020, and December 23, 2021, 58 patients were enrolled, and all were included in the efficacy and safety analysis set. The objective response rate was 65.5% (95% CI, 51.9 to 77.5), and the disease control rate was 86.2% (95% CI, 74.6 to 93.9). The median duration of response was not reached, and the median progression-free survival was 10.4 months (95% CI, 7.2 to 13.6), with a median follow-up duration of 12.4 months (range, 2.1-19.9 months). Treatment-related adverse events (TRAEs) of grade 3 or higher were reported in 34 (58.6%) patients, with the most common being hypertension (19.0%), nasopharyngeal necrosis (15.5%), headache (12.1%), AST elevation (10.3%), and creatine phosphokinase elevation (10.3%). Sixteen (27.6%) patients discontinued apatinib treatment before progression because of unbearable TRAEs, and the most common complication was nasopharyngeal necrosis (9/16; 56.3%). Recurrent nasopharyngeal lesions (odds ratio, 5.94 [95% CI, 1.45 to 24.24]) and reirradiation (odds ratio, 5.33 [95% CI, 1.15 to 24.79]) were significantly positively correlated with nasopharyngeal necrosis.CONCLUSIONCamrelizumab plus apatinib had promising antitumor activity in patients with refractory recurrent/metastatic NPC who failed first-line therapy. Moderate to severe TRAEs were experienced by 58.6%, including nasopharyngeal necrosis associated with local recurrence and a history of reirradiation.

学科与关键词

关键词
RENAL-CELL CARCINOMATUMOR MICROENVIRONMENTANTITUMOR-ACTIVITYPEMBROLIZUMABBLOCKADESAFETYMULTICENTERCOMBINATIONSORAFENIBCISPLATIN
相关
加载中…
  • Camrelizumab plus apatinib in patients with recurrent or metastatic nasopharyngeal carcinoma failing first-line therapy: An open-label, single-arm, phase II study
    Ding, X.; Zhang, W.; You, R.; Zou, X.; Wang, Z.; Ouyang, Y-F.; Liu, Y-L.; Peng, L.; You-Ping, L.; Duan, C-Y.; Yang, Q.; Lin, C.; Yulong, X.; Chen, S-Y.; Gu, C-M.; Huang, P. Y.; Hua, Y.; Chen, M.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), ELECTR NETWORK, 2022-09-09 To 2022-09-13.
  • The efficacy and safety of apatinib plus capecitabine in platinum-refractory metastatic and/or recurrent nasopharyngeal carcinoma: a prospective, phase II trial
    Tang, Lin-Quan; Li, Xiao-Yun; Li, Zhi-Ming; Liu, Zhi-Gang; Lin, Miao-Zhen; Zhou, Huan; Yu, Qi-Wen; Zhou, Jian; Zhao, Chong; Chen, Ze-Bin; Wang, Xi-Cheng; Peng, Jia-Yu; Chen, Qiu-Yan; Fang, Wen-Feng; Yang, Yun-Peng; Zhang, Bei; Xia, Liang-Ping; Hu, Pi-Li; Hu, Wei-Han; Li, Yi-Jie; Mai, Hai-Qiang; Cai, Xiu-Yu*BMC Medicine, 2023, 21(1): 94.
  • Efficacy and safety of camrelizumab plus apatinib as second-line treatment for advanced squamous non-small cell lung cancer
    Gao, Guanghui; Zhao, Jun; Ren, Shengxiang; Wang, Yina; Chen, Gongyan; Chen, Jianhua; Gu, Kangsheng; Guo, Renhua; Pan, Yueyin; Wang, Quanren; Li, Weixia; Yang, Xinfeng; Zhou, Caicun*Annals of Translational Medicine, 2022, 10(8): 441.被引 11
查看全部 →

发表信息

论文状态
公开发表
期刊
Journal of Clinical Oncology
发表日期
2023-05-10
卷期
第 41 卷, 第 14 期
页码
2571-+
DOI
10.1200/JCO.22.01450
语言
ENGLISH
成果收录
SCIE
资助标注
National Natural Science Foundation of China [81772895, 82002857, 82230034]; Key-Area Research and Development of Guangdong Province [2020B1111190001]; Special Support Program for High-level Talents in Sun Yat-sen University Cancer Center; Guangzhou Science and Technology Plan Project [202103010001]; National Ten Thousand Talents Program Science and Technology Innovation Leading Talents [84000-41180005]

作者

  • D

    Ding, Xi (第一作者)

    sun yat sen univ

  • Z

    Zhang, Wei-Jing

    sun yat sen univ

查看全部 20 位作者收起作者
  • Y

    You, Rui

    sun yat sen univ

  • Z

    Zou, Xiong

    sun yat sen univ

  • W

    Wang, Zhi-Qiang

  • O

    Ouyang, Yan-Feng

    sun yat sen univ

  • P

    Peng, Lan

    sun yat sen univ

  • L

    Liu, You-Ping

  • D

    Duan, Chong-Yang

  • Y

    Yang, Qi

    sun yat sen univ

  • L

    Lin, Chao

    sun yat sen univ

  • X

    Xie, Yu-Long

    sun yat sen univ

  • C

    Chen, Si-Yuan

    sun yat sen univ

  • L

    Liu, Yong-Long

  • G

    Gu, Chen-Mei

    sun yat sen univ

  • X

    Xie, Ruo-Qi

    sun yat sen univ

  • H

    Huang, Pei-Yu

    sun yat sen univ

  • H

    Hong, Ming-Huang

    sun yat sen univ

  • H

    Hua, Yi-Jun

    sun yat sen univ

  • C

    Chen, Ming-Yuan

    sun yat sen univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417